28
Oct
2025
Vectura Ltd.
Exhibitor at CPHI Frankfurt 2025 stand 5.0D100
About Us
Categories
-
GB
-
2020On CPHI since
-
250 - 499Employees
Company types
Event information
CPHI Frankfurt 2025
-
28 Oct 2025 - 30 Oct 2025
-
Messe, Frankfurt
-
Visit us at stand 5.0D100
Products Featured at CPHI Frankfurt 2025
-
Product Inhalation Device Platforms
Access the delivery technology best suited to the needs of your development programme, including unit-dose and multi-unit dose DPIs, pMDIs and smart nebulisers, suitable for home or hospital applications.
Dry Powder Inhalers:
Options include proprietary unit- and multi-unit dose platforms, as w... -
Product Inhaled Formulation Development
With expertise in powder and liquid formulations for small molecules and biologics, as well as a broad portfolio of proprietary device and formulation technologies, we can help you overcome the challenges of inhaled formulation development.
Dry Powder Formulation
Advanced po... -
Product Analytical Services - Inhaled Products
With extensive, state-of-the-art analytical testing facilities and equipment, our expert teams are able to develop and validate the methodologies required to characterise inhaled delivery platforms, especially DPI, pMDI and nebulised products.
To ensure seamless support for your development... -
Product Process Development & Inhaled Product Manufacturing
In addition to extensive development manufacturing facilities, Vectura has GMP manufacturing facilities for dry powder inhalers, pMDI and nebuliser medical devices as well as further capability to handle biological molecules.
Our GMP manufacturing facilities and equipment are relevant-to-comme... -
Product Medical & Regulatory Services - Inhaled Products
Our formulation, device and development services are supported by our medical, regulatory, device vigilance and pharmacovigilance teams to safeguard your programme and ensure the smoothest path to product approval.
Our in-house team can support with:
Global regulatory development strategy... -
Product Dry Powder Inhalers (DPI)
Our dry powder inhalers are derived from the commercially-validated AirFluSal® Gyrohaler® platform, but with a range of user interfaces and payload volumes, giving you confidence of performance and a proven regulatory track record.
With options for proprietary unit- and multi-unit dose platforms... -
Product SMART Nebulisers
Our state-of-the-art breath-actuated nebulisers with guided inhalation have been developed to improve lung delivery for inhaled drugs, with the aim of achieving better clinical outcomes and/or shortened treatment times.
FOX® nebuliser: handheld system that delivers high... -
Product Tailored Inhaled Development Services
From one-off studies and specialist techniques through to full development services, our inhalation services can support your programme through all stages of clinical development and get your product ready for commercial manufacturing.
We understand different customers may require different t...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance